Hemogenyx Pharmaceuticals (HEMO)

Company name:Hemogenyx Pharmaceuticals Plc
EPIC:HEMOTrading Currency:GBX
Market Sector:SQS3ISIN:GB00BYX3WZ24
Market Segment:SSQ3Share Type:DE
WWW Address:http://www.hemogenyx.com/Description:ORD GBP0.01
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Offer Open High Low Volume
 2.10 images.advfn.com/imagesnew/2/gb/dot 0.0 [0.00] 2.00 2.20 2.10 2.10 2.10 227,855
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 7.48 356.04 0.00 - - - - 4.28 - 1.75

Hemogenyx Pharmaceuticals Key Figures

(at previous day's close)
Market Cap.7.48m
Shares In Issue356.04m
Prev. Close2.10
PE Ratio- 
Dividend Yield-%
EPS - basic-p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-0.30p
Return On Equity (ROE)-154.04%
Operating Margin-%
PEG Factor- 
EPS Growth Rate100.00%
Dividends PS Growth Rate-%
Net Debt-0.33m
Gross Gearing58.29%
Quick Assets1.45m
Net Working Capital1.32m
Intangibles / Fixed Assets61.06%
Turnover PS-p
Pre-Tax Profit PS-0.34p
Retained Profit PS-0.33p
Cash PS0.39p
Net Cash PS0.35p
Net Tangible Asset Value PS *0.15p
Net Asset Value PS0.21p
Spread0.20 (9.09%) 

Hemogenyx Pharmaceuticals Balance Sheet

HEMO:Liabilities+EQHEMO:Assets

Share Price Performance

Sample Period HighLow
1 week2.452.05
4 weeks2.451.75
12 weeks2.751.75
1 year4.281.75

Share Price Chart (5 years)

Hemogenyx Pharmaceuticals Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week2.25-0.15-6.672.050.102.19
4 weeks1.900.2010.531.750.442.17
12 weeks2.50-0.40-16.001.750.332.21
26 weeks2.75-0.65-23.641.750.602.72
1 year2.45-0.35-14.291.750.732.79
3 years3.63-1.53-42.071.751.203.61
5 years3.63-1.53-42.071.751.203.61

Hemogenyx Pharmaceuticals Key Management Ratios

Hemogenyx Pharmaceuticals Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 3.18 
Tobin's Q Ratio (excl. intangibles)3.59 
Dividend Yield-%
Market-to-Book Ratio9.94 
Price-to-Pre-Tax Profit PS-6.27 
Price-to-Retained Profit PS-6.45 
Price-to-Cash Flow PS-7.05 
Price-to-Sales PS- 
Price-to-Net Tangible Asset Value PS13.89 
Price-to-Cash PS5.41 
Net Working Capital PS0.37 
Price Pct to Working Capital PS5.66%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Hemogenyx Pharmaceuticals Financial Ratios

(Leverage Ratios)
Debt Ratio55.01%
Debt-to-Equity Ratio1.22 
Debt-to-Equity Ratio (excl. Intgbl)1.71 
Debt-to-Equity Market Value0.12 
Net Gearing-18.35%
Net Gearing (excl. Intangibles)-20.82%
Gross Gearing58.29%
Gross Gearing (excl. Intangibles)66.13%
Gearing Under 1 Year7.29%
Gearing Under 1 Year (excl. Intgbl)8.27%
Assets/Equity2.40 
Cash/Equity183.75 
(Liquidity Ratios)
Net Working Capital to Total Assets73.29%
Current Ratio11.06 
Quick Ratio (Acid Test)11.06 
Liquidity Ratio10.52 
Cash & Equiv/Current Assets95.12%
(Solvency Ratios)
Enterprise Value7.01m
CFO/Sales- 
CFO/Attributable Profit- 
CFO/Assets-0.59 
CFO/Debt-1.01 
Total Debt/Equity Market Value0.14 
Total Debt/Sales- 
Total Debt/Pre-Tax Profit-0.88 
Total Debt1.05m
Total Debt/Net Current Assets0.80%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs- 
Beta (60-Mnth)Beta (36-Mnth)
0.00130.0013

Hemogenyx Pharmaceuticals Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-71.36%
Return On Assets (ROA)-49.35%
Net Profit Margin-%
Assets Turnover- 
Return On Equity (ROE)-154.04%
Return On Investment (ROI)-54.35%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-%
(Asset Utilisation Multiples)
Shareholders Equity Turnover- 
Fixed Assets Turnover- 
Current Assets Turnover- 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales- 
Debtors-to-Sales-%
Debt Collection Period-Days

Hemogenyx Pharmaceuticals Dividends

Sorry No Data Available

Hemogenyx Pharmaceuticals Fundamentals

 31 Dec 2017 (USD)31 Dec 2018 (USD)
turnover----m
pre tax profit-2.36--1.52-m
attributable profit-2.36--1.48-m
retained profit-2.36--1.48-m
eps - basic-1.00 - 
eps - diluted-1.00 - 
dividends per share- - 

Hemogenyx Pharmaceuticals Balance Sheet

 31 Dec 2017 (USD)31 Dec 2018 (USD)
HEMO:Liabilities+EQHEMO:AssetsHEMO:Liabilities+EQHEMO:Assets
 31 Dec 2017 (USD)31 Dec 2018 (USD)
ASSETS
fixed assets fixed assets0.198.00%0.177.56%m
intangibles intangibles0.2610.75%0.2711.86%m
fixed investments fixed investments--%--%m
current assets - other current assets - other--%--%m
stocks stocks--%--%m
debtors debtors0.072.91%0.093.93%m
cash & securities cash & securities1.8878.34%1.7676.64%m
TOTAL2.40100%2.30100%m
LIABILITIES
creditors - short creditors - short0.2611.01%0.177.29%m
creditors - long creditors - long--%1.1751.00%m
creditors - other creditors - other--%--%m
subordinated loans subordinated loans--%--%m
insurance funds insurance funds--%--%m
TOTAL0.2611.01%1.3458.29%m
EQUITY
ord cap, reserves ord cap, reserves2.1388.99%0.9641.71%m
prefs, minorities prefs, minorities--%--%m
TOTAL2.1388.99%0.9641.71%m
OTHER
NAV Basic- - 
NAV Diluted- - 

Hemogenyx Pharmaceuticals Cash Flow Statement

31 Dec 2017 (USD)31 Dec 2018 (USD)
Operating CF-0.45-1.35m
Pre-Financing CF0.58-1.35m
Retained CF1.80-0.02m

Hemogenyx Pharmaceuticals Brokers

Broker infomation is not available for this class of stock.
Your Recent History
LSE
HEMO
Hemogenyx ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191207 03:31:01